Navigation Links
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
Date:10/8/2008


-- Exploratory study shows clinical improvement in patients with pulmonary

arterial hypertension (PAH)

-- Current treatment options have limited benefit for this debilitating,

rapidly progressive and incurable blood vessel disease

-- Imatinib mesylate, available as Gleevec(R) for treatment of certain

cancers, known to inhibit protein associated with PAH

-- Novartis to further explore potential of imatinib mesylate in PAH in

2009

EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.

Preliminary findings from a 59-patient, multi-center Phase II clinical trial suggest imatinib mesylate provides a treatment benefit, as demonstrated by a significant improvement in pulmonary vascular resistance and a numerical increase in cardiac output, key hemodynamic measures used to monitor the progression of the disease. Improvements in the six-minute walk test, the primary endpoint of the study, approached, but did not reach, statistical significance.

These initial data were presented today at the European Respiratory Society (ERS) congress in Berlin, Germany, and further details on the study are expected to be published later this year. Imatinib mesylate is available for oncology indications as Gleevec(R) in the US, Canada and Israel and as Glivec(R) (imatinib), in countries outside of the US, Canada and Israel.

"The outcomes of this trial are clinically important given the rapid progression of PAH and the poor prognosis for these patients," said Professor Ardeschir Ghofrani, MD, Head of Pulmonary Hypertension Division, University Hospital Giessen und Marburg, Germany. "Our observations suggest that imatinib mesylate holds promise in treating PAH."

PAH is a de
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
2. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
5. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
6. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
7. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
8. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
9. Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
10. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... 2010 CareFusion (NYSE: ... today launched the EnVe™ ventilator , a ... 70-80 pounds lighter than other ventilators with similar ... The EnVe ventilator has the capability to ...
... Dec. 20, 2010 Codexis, Inc. (Nasdaq: CDXS ... Jaffray Clean Technology & Renewables Conference, to be held in ... be made by Robert Lawson, Senior Vice President and Chief ... noon Eastern Time.  A webcast and replay will be available ...
Cached Medicine Technology:CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 2CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 3
(Date:12/24/2014)... Dennis Thompson HealthDay ... There,s good news about the experimental Ebola vaccine that U.S. ... research shows a precursor of that vaccine produced a ... version of the vaccine, when given to more than 100 ... and white blood cells that could potentially protect a person ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Long-term fear of terrorists ... early death, a new study from Israel suggests. , , ... study involved 17,300 Israelis. In Israel, the threat of war ... than 60 years. "We wanted to test whether fear ... increased risk of death," study author Hermona Soreq, a professor ...
(Date:12/24/2014)... -- If you are a high-risk heart patient, you ... by a cardiologist, new research suggests. Survival rates ... for annual professional meetings, Harvard researchers report. Sixty ... to a teaching hospital during one of these meetings ... these meetings were not taking place. "That,s a ...
(Date:12/22/2014)... 2014 As early as thirty, gravity ... in the form of “jowls." The dreaded droopiness usually ... the marionette line or smile lines. Aging can be ... but as the deep facial tissues descend, jowls inevitably ... fillers that can be used under the skin to ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting ... their ad hoc report writing service to meet the ... up for an annual subscription and get a fixed ... deeply discounted hourly rate. , Customers can choose ... discounted rate. Subscription hours are contracted in 25 hour ...
Breaking Medicine News(10 mins):Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3
... Speaker Nancy Pelosi,delivered remarks this morning at the ... members of Congress, and hundreds of,children and seniors. ... full,funding of the State Children,s Health Insurance Program ... ask me what the three most important issues ...
... BETHESDA, Md., Sept. 6 Montana native and health ... Center Billings, MT, has been,installed to the post ... Health Centers (NACHC). Ceremonies took place at NACHC,s ... in Dallas, TX,which drew thousands of health center ...
... to make open-heart,surgery a minimally invasive procedure ... of Health Bioengineering Research Partnership award.,Professor Pierre ... surgeon Pedro del Nido, M.D., at Children,s ... Inc. (Van Nuys,CA) will collaborate to develop ...
... finds it brings the patient real benefit, too , ... partners with Alzheimer,s disease report better physical health if ... shows. , "Preserving the health of spouse caregivers through ... disease, as caregivers who are in poor health are ...
... 6 In response to,reports about the potential closure ... today reassured employees that the,civil section of the facility ... of closing the civil section of Warren,State Hospital and ... in,which residents and counties have come to depend," said ...
... on most common cause of inherited mental ... impairment and Parkinson-like syndrome, SAN FRANCISCO, ... California, Davis, School of Medicine and the M.I.N.D.,Institute, in collaboration ... Interdisciplinary Research Consortium grant from,the National Institutes of Heath, the ...
Cached Medicine News:Health News:Pelosi: SCHIP Bill a Giant Step for America's Children 2Health News:Montana Health Care Leader Elected Board Chair of National Association 2Health News:Minimally Invasive Heart Surgery Research Wins N.I.H. Award 2Health News:Counseling Boosts Alzheimer's Caregivers' Health 2Health News:PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors 2Health News:$21.8 Million NIH Grant for Fragile X Research 2Health News:$21.8 Million NIH Grant for Fragile X Research 3Health News:$21.8 Million NIH Grant for Fragile X Research 4
... The VacoSplint has a rigid shell with ... an immobilized foot/ankle. The VacoSplint is a non-weight ... weight bear he/she should transfer to the STORM ... remove the nylon liner from the STORM and ...
The Active Ankle Trainer model provides medial/lateral support and optimum ankle mobility for chronic and prophylactic use....
... Walker Pediatric Boot is the ... boot that offers superior comfort ... two sizes are offered thus ... will fit left or right, ...
... features a more open design of our ... Conformer boots. It is used to treat ... patients, plantar fasciitis, bone bruises (stone bruises), ... foot condition that might respond well to ...
Medicine Products: